Axsome Therapeutics, Inc. (LON:0HKF)
London
· Delayed Price · Currency is GBP · Price in USD 135.37
+7.14 (5.57%)
Feb 21, 2025, 4:31 PM BST
Axsome Therapeutics Revenue
In the year 2024, Axsome Therapeutics had annual revenue of $385.69M USD with 42.53% growth. Axsome Therapeutics had revenue of $118.77M in the quarter ending December 31, 2024, with 66.04% growth.
Revenue
$385.69M
Revenue Growth
+42.53%
P/S Ratio
n/a
Revenue / Employee
$707.69K
Employees
545
Market Cap
5.31B GBP
Revenue Chart
* This company reports financials in USD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.19B |
| GSK plc | 31.38B |
| Haleon | 11.24B |
| Smith & Nephew | 4.46B |
| Hikma Pharmaceuticals | 2.39B |
| ConvaTec Group | 1.74B |
| HUTCHMED (China) | 483.31M |
| Oxford Nanopore Technologies | 167.75M |
Axsome Therapeutics News
- 23 days ago - Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader - GlobeNewsWire
- 23 days ago - Axsome gets FDA approval for Symbravo for migraine - Seeking Alpha
- 23 days ago - Axsome Therapeutics Inc (AXSM) Announces FDA Approval of SYMBRAVO for Migraine Treatment - GuruFocus
- 23 days ago - US FDA approves Axsome Therapeutics' migraine drug - Reuters
- 23 days ago - Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults - GlobeNewsWire
- 5 weeks ago - Axsome Therapeutics expects Q4 and FY24 revenue marginally higher than consensus - Seeking Alpha
- 5 weeks ago - Axsome Therapeutics Inc (AXSM) Reports Strong Preliminary 2024 Revenue Growth - GuruFocus
- 7 weeks ago - Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results - Seeking Alpha